The Business Research Company’s 2026 market reports feature advanced enhancements such as market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, delivering more actionable and strategically valuable research.
What Will Be The Estimated Market Size Of The Neulasta Market By 2030?
Historically, the observed growth was propelled by various factors, including the expanding application of chemotherapy, a heightened occurrence of treatment-induced neutropenia, the widespread availability of pegylated growth factors, the development of more comprehensive oncology supportive care protocols, and the increasing adoption of prefilled injection devices.
The anticipated growth during the forecast period is fueled by an escalating demand for convenient drug delivery systems, increasing investments in biosimilar competition, the expansion of oncology treatments administered at home, a heightened focus on patient-centric cancer care, and the growing adoption of long-acting biologics. Furthermore, significant trends expected within this period encompass the increasing use of long-acting neutropenia treatments, a rise in the deployment of on-body injector systems, the expansion of supportive oncology care services, a growing preference for managing cancer in outpatient settings, and an enhanced emphasis on ensuring treatment adherence.
Download A Free Sample Report For Comprehensive Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=20159&type=smp
What Core Drivers Are Transforming The Neulasta Market?
The increase in cancer cases is anticipated to fuel the expansion of the neulasta market. Cancer, characterized by uncontrolled cell growth that can spread throughout the body, is becoming more prevalent largely due to an aging global population, as the risk of developing the disease significantly rises with age. Neulasta, a therapy based on pegfilgrastim, plays a vital role in cancer treatment by preventing neutropenia caused by chemotherapy, encouraging white blood cell production, and thereby lowering the risk of infections for patients undergoing such treatments. For example, data from August 2024 by the Australian Institute of Health and Welfare indicates that Australia is expected to see approximately 209,000 new cancer cases by 2034, an increase from an estimated 169,000 cases in 2024, with cancer projected to be responsible for around three out of every ten deaths in 2024. Consequently, the growing occurrence of cancer will propel the neulasta market.
What Segment Types Are Included In The Neulasta Market Analysis?
The neulasta market covered in this report is segmented –
1) By Indication: Chemotherapy-Induced Neutropenia, Bone Marrow Transplantation, Other Indications
2) By Formulation: Injectable Solution, Pre-Filled Syringes Or Pens
3) By Distribution Channel: Hospitals, Oncology Clinics, Specialty Pharmacies, Home Healthcare Services
4) By End User Patients: Adult Patients, Pediatric Patients
Which Trends Are Influencing The Expansion Of The Neulasta Market?
The primary trend observed within the neulasta market revolves around the advancement of drug delivery technologies, particularly prefilled autoinjectors, aimed at securing a competitive edge in the sector. These prefilled autoinjectors are self-administration tools that come pre-loaded with medication, making self-injection convenient and straightforward for patients. As an illustration, in March 2023, Coherus Biosciences, a US-based biopharmaceutical firm, announced that the FDA had given its approval for a single-dose, prefilled autoinjector variant of its pegfilgrastim biosimilar, Udenyca (pegfilgrastim-cbqv). This approval is specifically for the management and prevention of febrile neutropenia, a frequent side effect of chemotherapy. This innovative autoinjector enables patients to administer pegfilgrastim the day following chemotherapy, thereby lowering the probability of developing febrile neutropenia. The device is characterized by its push-on-skin activation mechanism, ensuring consistent and prompt delivery of a complete pegfilgrastim dose.
Which Organizations Are Operating Within The Neulasta Market?
Major companies operating in the neulasta market are Amgen Inc.
Access The Complete Neulasta Market Report:
https://www.thebusinessresearchcompany.com/report/neulasta-global-market-report
Which Region Is The Dominant Market In The Neulasta Market?
North America was the largest region in the neulasta market in 2025. The regions covered in the neulasta market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model